KLRS — Kalaris Therapeutics Balance Sheet
0.000.00%
- $86.59m
- -$1.83m
Annual balance sheet for Kalaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 356 | 248 | 234 | 184 | 118 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.45 | 0.05 | 0.157 | 0.206 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 361 | 253 | 243 | 188 | 119 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.5 | 31.3 | 32.6 | 2.19 | — |
| Other Long Term Assets | |||||
| Total Assets | 371 | 287 | 277 | 191 | 119 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12.3 | 37.9 | 24.3 | 28.4 | 5.24 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 17.8 | 61.3 | 52.6 | 45 | 5.24 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 353 | 225 | 225 | 146 | 113 |
| Total Liabilities & Shareholders' Equity | 371 | 287 | 277 | 191 | 119 |
| Total Common Shares Outstanding |